skip to main content
Idioma:
Refinado por: Nome da Publicação: The Lancet Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Choueiri, Toni K, Dr ; Escudier, Bernard, MD ; Powles, Thomas, Prof ; Tannir, Nizar M, Prof ; Mainwaring, Paul N, MD ; Rini, Brian I, Prof ; Hammers, Hans J, MD ; Donskov, Frede, MD ; Roth, Bruce J, Prof ; Peltola, Katriina, MD ; Lee, Jae Lyun, Prof ; Heng, Daniel Y C, MD ; Schmidinger, Manuela, Prof ; Agarwal, Neeraj, MD ; Sternberg, Cora N, Prof ; McDermott, David F, MD ; Aftab, Dana T, PhD ; Hessel, Colin, MS ; Scheffold, Christian, MD ; Schwab, Gisela, MD ; Hutson, Thomas E, Prof ; Pal, Sumanta, MD ; Motzer, Robert J, Prof

The lancet oncology, 2016-07, Vol.17 (7), p.917-927 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Fizazi, Karim, Prof Dr ; Scher, Howard I, Prof ; Molina, Arturo, MD ; Logothetis, Christopher J, Prof ; Chi, Kim N, MD ; Jones, Robert J, PhD ; Staffurth, John N, MD ; North, Scott, MD ; Vogelzang, Nicholas J, MD ; Saad, Fred, Prof ; Mainwaring, Paul, MD ; Harland, Stephen, MD ; Goodman, Oscar B, MD ; Sternberg, Cora N, MD ; Li, Jin Hui, PhD ; Kheoh, Thian, PhD ; Haqq, Christopher M, MD ; de Bono, Johann S, Prof

The lancet oncology, 2012-10, Vol.13 (10), p.983-992 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

Fizazi, Karim, Prof ; Scher, Howard I, Prof ; Miller, Kurt, Prof ; Basch, Ethan, MD ; Sternberg, Cora N, MD ; Cella, David, Prof ; Forer, David, MSc ; Hirmand, Mohammad, MD ; de Bono, Johann S, Prof

The lancet oncology, 2014-09, Vol.15 (10), p.1147-1156 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Loriot, Yohann, Dr ; Miller, Kurt, Prof ; Sternberg, Cora N, Prof ; Fizazi, Karim, Prof ; De Bono, Johann S, Prof ; Chowdhury, Simon, PhD ; Higano, Celestia S, MD ; Noonberg, Sarah, MD ; Holmstrom, Stefan, MSc ; Mansbach, Harry, MD ; Perabo, Frank G, MD ; Phung, De, BSc ; Ivanescu, Cristina, PhD ; Skaltsa, Konstantina, PhD ; Beer, Tomasz M, Prof ; Tombal, Bertrand, Prof

The lancet oncology, 2015-05, Vol.16 (5), p.509-521 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Motzer, Robert J, Dr Prof ; Porta, Camillo, MD ; Vogelzang, Nicholas J, Prof ; Sternberg, Cora N, MD ; Szczylik, Cezary, Prof ; Zolnierek, Jakub, MD ; Kollmannsberger, Christian, MD ; Rha, Sun Young, MD ; Bjarnason, Georg A, MD ; Melichar, Bohuslav, Prof ; De Giorgi, Ugo, MD ; Grünwald, Viktor, Prof ; Davis, Ian D, MBBS ; Lee, Jae-Lyun, Prof ; Esteban, Emilio, Prof ; Urbanowitz, Gladys, MBA ; Cai, Can, PhD ; Squires, Matthew, PhD ; Marker, Mahtab, PhD ; Shi, Michael M, MD ; Escudier, Bernard, Prof

The lancet oncology, 2014-03, Vol.15 (3), p.286-296 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

Tran, Hai T, PharmD ; Liu, Yuan, PhD ; Zurita, Amado J, MD ; Lin, Ying, PhD ; Baker-Neblett, Katherine L, MBA ; Martin, Anne-Marie, PhD ; Figlin, Robert A, MD ; Hutson, Thomas E, DO ; Sternberg, Cora N, MD ; Amado, Rafael G, MD ; Pandite, Lini N, MD ; Heymach, John V, Dr

The lancet oncology, 2012-08, Vol.13 (8), p.827-837 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial

Logothetis, Christopher J, Prof ; Basch, Ethan, MD ; Molina, Arturo, MD ; Fizazi, Karim, Prof ; North, Scott A, MD ; Chi, Kim N, MD ; Jones, Robert J, MD ; Goodman, Oscar B, MD ; Mainwaring, Paul N, MD ; Sternberg, Cora N, MD ; Efstathiou, Eleni, MD ; Gagnon, Dennis D, MA ; Rothman, Margaret, PhD ; Hao, Yanni, PhD ; Liu, Cameron S, PhD ; Kheoh, Thian S, PhD ; Haqq, Christopher M, MD ; Scher, Howard I, Prof ; de Bono, Johann S, Prof

The lancet oncology, 2012-12, Vol.13 (12), p.1210-1217 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Material Type:
Artigo 		Adicionar ao Meu Espaço

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

Sonpavde, Guru, Dr ; Sternberg, Cora N, MD ; Rosenberg, Jonathan E, MD ; Hahn, Noah M, MD ; Galsky, Matthew D, MD ; Vogelzang, Nicholas J, MD

The lancet oncology, 2010-09, Vol.11 (9), p.861-870 [Periódico revisado por pares]

England: Elsevier Limited

Texto completo disponível

Citações Citado por
9
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

Sternberg, Cora N, Dr ; Castellano, Daniel, MD ; Daugaard, Gedske, Prof ; Géczi, Lajos, MD ; Hotte, Sebastien J, MD ; Mainwaring, Paul N, MD ; Saad, Fred, Prof ; Souza, Ciro, MD ; Tay, Miah H, MD ; Garrido, José M Tello, MD ; Galli, Luca, MD ; Londhe, Anil, PhD ; De Porre, Peter, MD ; Goon, Betty, BS ; Lee, Emma, PhD ; McGowan, Tracy, MD ; Naini, Vahid, PharmD ; Todd, Mary B, DO ; Molina, Arturo, MD ; George, Daniel J, MD

The lancet oncology, 2014-10, Vol.15 (11), p.1263-1268 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Tombal, Bertrand ; Saad, Fred ; Penson, David ; Hussain, Maha ; Sternberg, Cora N ; Morlock, Robert ; Ramaswamy, Krishnan ; Ivanescu, Cristina ; Attard, Gerhardt

The lancet oncology, 2019-04, Vol.20 (4), p.556-569 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.